Top

Published in:

Open Access 01-12-2016 | Case Report

Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report

Authors: Joseph Hatem, April M. Schrank-Hacker, Christopher D. Watt, Jennifer J. D. Morrissette, Adam I. Rubin, Ellen J. Kim, Sunita D. Nasta, Mariusz A. Wasik, Agata M. Bogusz

Published in: Diagnostic Pathology | Issue 1/2016

Abstract

Background

Diffuse large B-cell lymphoma (DLBCL) typically leads to effacement of the nodal architecture by an infiltrate of malignant cells. Rarely (<1%), DLBCL can present with an interfollicular pattern (DLBCL-IF) preserving the lymphoid follicles. It has been postulated that DLBCL-IF is derived from marginal zone B cells and may represent a large-cell transformation of marginal zone lymphoma (MZL), however no direct evidence has been provided to date. Here we describe a rare case of a diagnostically challenging DLBCL-IF involving a lymph node in a patient with a prior history of lymphadenopathy for several years and MZL involving skin.

Case presentation

A 53-year old man presented to our Dermatology Clinic due to a 1-year history of generalized itching, fatigue of 2–3 month’s duration, nausea and mid back rash that was biopsied. PET (positron emission tomography)/CT (computed tomography) was performed and revealed inguinal, pelvic, retroperitoneal, axillary, and cervical lymphadenopathy. The patient was referred to surgery for excisional biopsy of a right inguinal lymph node.

Diagnostic H&E stained slides and ancillary studies were reviewed for the lymph node and skin specimens. B-cell clonality by PCR and sequencing studies were performed on both specimens.

We demonstrate that this patient’s MZL and DLBCL-IF are clonally related, strongly suggesting that transformation of MZL to DLBCL had occurred. Furthermore, we identified a novel deletion of the long arm of chromosome 20 (del(20q12)) and a missense mutation in BIRC3 (Baculoviral IAP repeat-containing protein 3) in this patient’s DLBCL that are absent from his MZL, suggesting that these genetic alterations contributed to the large cell transformation.

Conclusions

To our knowledge, this is the first report providing molecular evidence for a previously suspected link between MZL and DLBCL-IF. In addition, we describe for the first time del(20q12) and a missense mutation in BIRC3 in DLBCL. Our findings also raise awareness of DLBCL-IF and discuss the diagnostic pitfalls of this rare entity.

Swerdlow Sh CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J. WHO classification of tumours of haematopoietic and lymphoid tissues, vol 4th edition. World Health Organization and classification of tumours. Lyon: International Agency for Research on Cancer (IARC); 2008.

Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann hematol. 2014;93(8):1263–77. doi:10.1007/s00277-014-2116-y.CrossRefPubMedPubMedCentral

Gifford GK, Gill AJ, Stevenson WS. Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists. Pathology. 2016;48(1):5–16. doi:10.1016/j.pathol.2015.11.017.CrossRefPubMed

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi:10.1038/35000501.CrossRefPubMed

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. doi:10.1182/blood-2003-05-1545.CrossRefPubMed

Yamauchi A, Ikeda J, Nakamichi I, Kohara M, Fukuhara S, Hino M, Kanakura Y, Ogawa H, Sugiyama H, Kanamaru A, Aozasa K, Osaka Lymphoma Study G. Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group. Histopathology. 2008;52(6):731–7. doi:10.1111/j.1365-2559.2008.03018.x.CrossRefPubMed

Wada N, Zaki MA, Kohara M, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Inagaki H, Morii E, Aozasa K. Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group. Histopathology. 2012;60(6):924–32. doi:10.1111/j.1365-2559.2011.04161.x.CrossRefPubMed

Marafioti T, Jones M, Facchetti F, Diss TC, Du MQ, Isaacson PG, Pozzobon M, Pileri SA, Strickson AJ, Tan SY, Watkins F, Mason DY. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood. 2003;102(8):2868–76. doi:10.1182/blood-2003-03-0692.CrossRefPubMed

Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M. A modified integrated genetic model for risk prediction in younger patients with acute myeloid leukemia. Plos one. 2016;11(4):e0153016. doi:10.1371/journal.pone.0153016.CrossRefPubMedPubMedCentral

10.

Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N engl j med. 2012;366(12):1079–89. doi:10.1056/NEJMoa1112304.CrossRefPubMedPubMedCentral

11.

Daber R, Sukhadia S, Morrissette JJ. Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer genet. 2013;206(12):441–8. doi:10.1016/j.cancergen.2013.11.005.CrossRefPubMed

12.

Kern JB, Duff DJ, Odem JL, Esebua M, Smith LR, Doll D, Wang M. A novel del(20q) in aggressive nodal marginal zone lymphoma. Case rep pathol. 2013;2013:784176. doi:10.1155/2013/784176.PubMedPubMedCentral

13.

Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br j haematol. 1996;95(2):219–26.CrossRefPubMed

14.

Pellagatti A, Boultwood J. The molecular pathogenesis of the myelodysplastic syndromes. Eur j haematol. 2015;95(1):3–15. doi:10.1111/ejh.12515.CrossRefPubMed

15.

Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K. Deletion (20q) as the sole abnormality in waldenstrom macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer genet cytogenet. 2006;169(1):69–72. doi:10.1016/j.cancergencyto.2006.03.013.CrossRefPubMed

16.

Pradhan D, Amin RM, Jones MW, Surti U, Parwani AV. Giant cell arteritis of the female genital tract with occult temporal arteritis and marginal zone lymphoma harboring novel 20q deletion: a case report and literature review. Int j surg pathol. 2016;24(1):78–84. doi:10.1177/1066896915605165.CrossRefPubMed

17.

Yin CC, Tang G, Lu G, Feng X, Keating MJ, Medeiros LJ, Abruzzo LV. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. Mod pathol. 2015;8:1130–7. doi:10.1038/modpathol.2015.58.CrossRef

18.

Yin CC, Peng J, Li Y, Shamanna RK, Muzzafar T, Dinardo C, Khoury JD, Li S, Medeiros LJ, Wang SA, Tang G. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod pathol. 2015;28(8):1014–22. doi:10.1038/modpathol.2015.66.CrossRefPubMed

19.

Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013;2:e00825. doi:10.7554/eLife.00825.CrossRefPubMedPubMedCentral

20.

Futterer A, Campanero MR, Leonardo E, Criado LM, Flores JM, Hernandez JM, San Miguel JF, Martinez AC. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J clin invest. 2005;115(9):2351–62. doi:10.1172/JCI24177.CrossRefPubMedPubMedCentral

21.

Gurvich N, Perna F, Farina A, Voza F, Menendez S, Hurwitz J, Nimer SD. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc natl acad sci u s a. 2010;107(52):22552–7. doi:10.1073/pnas.1017092108.CrossRefPubMedPubMedCentral

22.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wright Colopy G, Dreau H, Sigaux F, Judde JG, Rotger M, Telenti A, Lin YL, Pasero P, Maelfait J, Titsias M, Cohen DR, Henderson SJ, Ross MT, Bentley D, Hillmen P, Pettitt A, Rehwinkel J, Knight SJ, Taylor JC, Crow YJ, Benkirane M, Schuh A. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood. 2014;123(7):1021–31. doi:10.1182/blood-2013-04-490847.CrossRefPubMedPubMedCentral

23.

Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat genet. 2011;43(9):830–7. doi:10.1038/ng.892.CrossRefPubMedPubMedCentral

24.

Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat rev mol cell biol. 2005;6(4):287–97. doi:10.1038/nrm1621.CrossRefPubMed

25.

Silke J, Vucic D. IAP family of cell death and signaling regulators. Methods enzymol. 2014;545:35–65. doi:10.1016/B978-0-12-801430-1.00002-0.CrossRefPubMed

26.

Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr mol med. 2011;11(8):633–49.CrossRefPubMed

27.

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Fama R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foa R, Gaidano G. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12):2854–62. doi:10.1182/blood-2011-12-395673.CrossRefPubMed

28.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foa R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930–4. doi:10.1182/blood-2011-06-359166.CrossRefPubMed

29.

Yang Y, Kelly P, Shaffer AL, 3rd, Schmitz R, Yoo HM, Liu X, Huang da W, Webster D, Young RM, Nakagawa M, Ceribelli M, Wright GW, Yang Y, Zhao H, Yu X, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Staudt LM. Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma. Cancer cell. (2016);29(4):494–507. doi:10.1016/j.ccell.2016.03.006

30.

Yamaguchi H, Hung MC. Regulation and role of EZH2 in cancer. Cancer res treat. 2014;46(3):209–22. doi:10.4143/crt.2014.46.3.209.CrossRefPubMedPubMedCentral

31.

Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J. EZH2 in normal hematopoiesis and hematological malignancies. Oncotarget. 2016;7(3):2284–96. 10.18632/oncotarget.6198.PubMed

32.

Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat genet. (2010);42(2):181–185. doi:10.1038/ng.518

33.

Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat med. 2016;22(2):128–34. doi:10.1038/nm.4036.CrossRefPubMedPubMedCentral

34.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra 3rd A, Diaz E, Lafrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, Mchugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–12. doi:10.1038/nature11606.CrossRefPubMed

35.

Yu YL, Su KJ, Hsieh YH, Lee HL, Chen TY, Hsiao PC, Yang SF. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. Plos one. 2013;8(9):e74870. doi:10.1371/journal.pone.0074870.CrossRefPubMedPubMedCentral

36.

Paolicchi E, Pacetti P, Giovannetti E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncol lett. 2013;6(5):1487–91. doi:10.3892/ol.2013.1559.PubMedPubMedCentral

37.

Ma ZB, Guo GH, Niu Q, Shi N. Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population. Int j mol sci. 2014;15(7):12688–97. doi:10.3390/ijms150712688.CrossRefPubMedPubMedCentral

38.

Yu YL, Su KJ, Hsieh MJ, Wang SS, Wang PH, Weng WC, Yang SF. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features. Plos one. 2014;9(4):e93635. doi:10.1371/journal.pone.0093635.CrossRefPubMedPubMedCentral

Title: Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report
Authors: Joseph Hatem
April M. Schrank-Hacker
Christopher D. Watt
Jennifer J. D. Morrissette
Adam I. Rubin
Ellen J. Kim
Sunita D. Nasta
Mariusz A. Wasik
Agata M. Bogusz
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-016-0588-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report

Abstract

Background

Case presentation

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Erratum to: Morphometrical analysis of transbronchial cryobiopsies

Intraoperative fine needle aspirations - diagnosis and typing of lung cancer in small biopsies: challenges and limitations

Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature

Primary pure spindle cell carcinoma (sarcomatoid carcinoma) of the ovary: A case report with immunohistochemical study